Role of PCSK9 inhibitors in the management of dyslipidaemia

Abstract

Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with or without bempedoic acid or those intolerant to statins.

Keywords

• PCSK9 inhibitors
• Dyslipidaemia
• LDL
• Familial hyperlipidemia